Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine iNeo-Vac-P01 in Resected Pancreatic Cancer
NCT04810910Phase 1Unknown
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iNeo-Vac-P01 in pancreatic adenocarcinoma (PDAC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Number of participants experiencing clinical and laboratory adverse events (AEs) at 1 year and Relapse Free Survival at 4 years. Status: unknown.
02
Drugs
iNeo-Vac-P01
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04810910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810910.